Guest guest Posted December 13, 2006 Report Share Posted December 13, 2006 The following is a response from my inquiry on the CMT and Theragenex info: ------------------------------------------------------------------- Ms. Glick, Thanks for your e-mail regarding our August press release. I have not personally met Dr. Shapiro; rather, our business dealings have been with Secant Pharma, to whom he assigned his 14 global patents. Currently, we are developing products for diabetes, cardiovascular disease, osteoarthritis, and osteoporosis. These products are being developed and marketed within our operating subsidiary, Zylera Pharmaceuticals (www.zylera.com). Since we are a small specialty pharma company, we felt that these therapeutic areas had the broadest scope and consequently they are the first in our pipeline. Please let me know if I can be of further assistance. Regards, Preston -------------------------------------------------------------------- Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.